Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled SAR442168 excretion and pharmacokinetics study in healthy males
NCT04171310Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tolebrutinib in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoint: Percentage of radioactive dose excreted in urine and feces. Started Nov 2019; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04171310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171310.